Peripheral blood-based cell signature indicates response to interstitial brachytherapy in primary liver cancer.
Biomarker
Blood cells
Brachytherapy
Flow cytometry
Liver cancer
Response prediction
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
25
04
2023
accepted:
19
05
2023
medline:
16
8
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Biomarkers are essential to implement personalized therapies in cancer treatment options. As primary liver tumors are increasing and treatment is coupled to liver function and activation of systemic cells of the immune system, we investigated blood-based cells for their ability to predict response to local ablative therapy. We analyzed peripheral blood cells in 20 patients with primary liver cancer at baseline and following brachytherapy. In addition to platelets, leukocytes, lymphocytes, monocytes, neutrophils and most common ratios PLR, LMR, NMR and NLR, we investigated T cell and NKT cell populations of 11 responders and 9 non-responders using flow cytometry. We have found a peripheral blood cell signature that differed significantly between responders and non-responders treated with interstitial brachytherapy (IBT). At baseline, non-responders featured higher numbers of platelets, monocytes and neutrophils, a higher platelet-to-lymphocyte ratio and an increase in the NKT cell population with a concurrent reduction in CD16 + NKT cells. Simultaneously, a lower percentage of CD4 + T cells was present in non-responders, as also reflected in a lower CD4/8 ratio. CD45RO + memory cells were lower in both, CD4 + and CD8 + T cell populations whereas PD-1 + T cells were only present in the CD4 + T cell population. Baseline blood-based cell signature may function as a biomarker to predict response following brachytherapy in primary liver cancer.
Identifiants
pubmed: 37247078
doi: 10.1007/s00432-023-04875-z
pii: 10.1007/s00432-023-04875-z
pmc: PMC10423129
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9777-9786Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2019 Jul 20;11(7):
pubmed: 31330817
World J Gastroenterol. 2015 Apr 28;21(16):4961-8
pubmed: 25945010
Cancer Growth Metastasis. 2018 Mar 09;11:1179064418761639
pubmed: 29551910
Front Oncol. 2022 Oct 24;12:959987
pubmed: 36353535
Hepatology. 2013 Jul;58(1):139-49
pubmed: 22961630
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Gut. 2020 Nov;69(11):2025-2034
pubmed: 32883873
Br J Cancer. 2018 Jan;118(2):248-257
pubmed: 29123264
Semin Radiat Oncol. 2011 Oct;21(4):287-93
pubmed: 21939858
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
Nat Med. 2022 Aug;28(8):1599-1611
pubmed: 35739268
Clin Cancer Res. 2022 Sep 1;28(17):3890-3901
pubmed: 35763041
Cancer Imaging. 2022 Jan 4;22(1):2
pubmed: 34983650
J Contemp Brachytherapy. 2021 Aug;13(4):458-467
pubmed: 34484362
Br J Cancer. 2008 Nov 18;99(10):1704-11
pubmed: 18941457
J Clin Invest. 2015 Sep;125(9):3413-21
pubmed: 26258412
PLoS One. 2019 Aug 16;14(8):e0221301
pubmed: 31419253
Clin Transl Radiat Oncol. 2018 Jul 06;12:8-15
pubmed: 30073209
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Nature. 2012 Feb 08;482(7385):405-9
pubmed: 22318517
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72
pubmed: 22753481
Oncoimmunology. 2021 Nov 9;10(1):2002068
pubmed: 34777920
J Immunol. 2007 Feb 1;178(3):1914-22
pubmed: 17237442
Front Oncol. 2022 Oct 31;12:1028728
pubmed: 36387149
J Hepatol. 2022 Dec;77(6):1598-1606
pubmed: 36208844
Ann Transl Med. 2020 Apr;8(7):441
pubmed: 32395485
Cell Tissue Res. 2011 Jan;343(1):43-55
pubmed: 20734065
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5640-4
pubmed: 10318937
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Sci Rep. 2016 Sep 27;6:34310
pubmed: 27670158
BMC Cancer. 2014 Oct 03;14:744
pubmed: 25280428
J Transl Med. 2019 Oct 1;17(1):328
pubmed: 31570105
J Pers Med. 2021 Jan 16;11(1):
pubmed: 33467153
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Hepatology. 2018 Oct;68(4):1347-1360
pubmed: 29631332
Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):
pubmed: 34099555
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
PLoS One. 2021 Sep 1;16(9):e0256739
pubmed: 34469466
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
J Hepatol. 2012 Feb;56(2):412-8
pubmed: 21756858
BMJ Open. 2020 Nov 6;10(11):e038172
pubmed: 33158820
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503144
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):965-972
pubmed: 27113564
Front Immunol. 2018 Feb 27;9:367
pubmed: 29535734
Cancers (Basel). 2021 Jun 08;13(12):
pubmed: 34201284
Hepatology. 2019 Mar;69(3):1165-1179
pubmed: 30153337
World J Hepatol. 2015 Jul 18;7(14):1834-42
pubmed: 26207165